GSWM
JAZZ icon

Golden State Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Golden State Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-31
Closed -$4K – 1120
2019
Q1 		$4K Buy
+31
New +$4.04K ﹤0.01% 941

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Golden State Wealth Management's JAZZ Position: Q2 2019 in Review

Golden State Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 31 shares — an estimated $4K sold.

Golden State Wealth Management first reported a position in JAZZ in Q1 2019 and held it in 1 quarter. The position peaked at $4K in Q1 2019. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

  • Golden State Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Golden State Wealth Management sold 31 Jazz Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • Golden State Wealth Management first reported a position in Jazz Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Golden State Wealth Management's Jazz Pharmaceuticals position peaked at $4K in Q1 2019.
  • 416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Golden State Wealth Management's 13F filing for Q2 2019, filed 9 Aug 2019.